Zobrazeno 1 - 10
of 91
pro vyhledávání: '"Ningjing, Lin"'
Autor:
Ningjing Lin, Xiuhua Sun, Hui Zhou, Liqun Zou, Keshu Zhou, Lihong Liu, Haiyan Yang, Kai Hu, Qingqing Cai, Yao Liu, Jie Jin, Liling Zhang, Wenyu Li, Ye Guo, Wei Yang, Feng Luo, Zhenguang Wang, Rong Zhu, Lei Yang, Dan Song, Yuqin Song, Jun Zhu
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have a poor prognosis. Loncastuximab tesirine (Lonca), an antibody conjugate targeting CD19, has demonstrated significant clinical benefit in R/R DLBCL in a global phase
Externí odkaz:
https://doaj.org/article/f8f59c1272c6425db6c5b7bf6bcbf17a
Autor:
Yanfei Liu, Lingyan Ping, Yuqin Song, Yongjing Tang, Wen Zheng, Weiping Liu, Zhitao Ying, Chen Zhang, Meng Wu, Feier Feng, Ningjing Lin, Meifeng Tu, Jun Zhu, Yan Xie
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-10 (2024)
Abstract Background Classical Hodgkin lymphoma (cHL) is a highly curable disease, while novel therapy is needed for refractory or relapsed (R/R) patients. This phase II trial aimed to evaluate the role of camrelizumab plus gemcitabine and oxaliplatin
Externí odkaz:
https://doaj.org/article/fa08cf055ddf4c60af21f800463a0902
Autor:
Weiping Liu, Ningjing Lin, Xinqin Feng, Yan Xie, Chong You, Xiaohua Zhou, Yuqin Song, Jun Zhu
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 8, Iss 1, Pp 1-7 (2023)
Abstract Anti-programmed cell death-1 (anti-PD-1) therapies have shown a favorable efficacy and good tolerance for relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). However, there are limited data on long-term outcomes among patients wit
Externí odkaz:
https://doaj.org/article/863e73c0555f444fb157805503b93229
Autor:
Ying Deng, Duo Wang, Wenhua Zhao, Guanhua Qiu, Xiaoqi Zhu, Qin Wang, Tian Qin, Jiali Tang, Jinghang Jiang, Ningjing Lin, Lili Wei, Yichen Liu, Yuan Xie, Jie Chen, Liu Deng, Junjie Liu
Publikováno v:
Research, Vol 7 (2024)
Hyperthermia therapy is considered an effective anticancer strategy. However, high temperature can trigger an excessive inflammatory response, leading to tumor self-protection, immunosuppression, metastasis, and recurrence. To address this issue, we
Externí odkaz:
https://doaj.org/article/af2f125c141e430bb48bd53eb7a33ce7
Autor:
Wei Xu, Ru Feng, LI Wang, Huayuan Zhu, Keshu Zhou, Xiaorui Fu, Hongmei Jing, Yuqin Song, Junyuan Qi, Guohui Cui, Fei LI, Shaoyuan Wang, Hui Zhou, Wenbin Qian, Qingqing Cai, Xielan Zhao, Xutao Guo, Xiaolei Wei, Ningjing Lin, Zhongyuan Xu, Zheng Wang, Xiang Xiao, Jiale Dong, Yejiang Lou, Yue Shen, Yi Chen, Yu Chen, Fenlai Tan, Stephen Anthony, Jianyong LI
Publikováno v:
HemaSphere, Vol 7, p e324590c (2023)
Externí odkaz:
https://doaj.org/article/a0d0914f61e74b97ab82c826d9893290
Autor:
Zhaoting Bu, Jianjun Yang, Yan Zhang, Tao Luo, Chao Fang, Xiayi Liang, Qiuxia Peng, Duo Wang, Ningjing Lin, Kun Zhang, Weizhong Tang
Publikováno v:
Advanced Science, Vol 10, Iss 23, Pp n/a-n/a (2023)
Abstract Abnormal epigenetic regulation is identified to correlate with cancer progression and renders tumor refractory and resistant to reactive oxygen species (ROS)‐based anti‐tumor actions. To address it, a sequential ubiquitination and phosph
Externí odkaz:
https://doaj.org/article/f44eb88a66b54b92bd55d335b8a70b7c
Autor:
Zhitao Ying, Ting He, Xiaopei Wang, Wen Zheng, Ningjing Lin, Meifeng Tu, Yan Xie, Lingyan Ping, Chen Zhang, Weiping Liu, Lijuan Deng, Meng Wu, Feier Feng, Xin Leng, Tingting Du, Feifei Qi, Xuelian Hu, Yanping Ding, Xin-an Lu, Yuqin Song, Jun Zhu
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background The unprecedented efficacy of chimeric antigen receptor T (CAR-T) cell immunotherapy of CD19+ B-cell malignancies has opened a new and useful way for the treatment of malignant tumors. Nonetheless, there are still formidable chall
Externí odkaz:
https://doaj.org/article/921e55332f6c4de6b40c7b6e7c6cebc4
Autor:
Chaoting Zhang, Heyilimu Palashati, Zhuona Rong, Ningjing Lin, Luyan Shen, Ying Liu, Shance Li, Bentong Yu, Wenjun Yang, Zheming Lu
Publikováno v:
Molecular Cancer, Vol 19, Iss 1, Pp 1-5 (2020)
Abstract Targeting T cell receptor β-chain constant region 1 (TRBC1) CAR-T could specifically kill TRBC1+ T-cell malignancies. However, over-expressed CARs on anti-TRBC1 CAR transduced TRBC1+ T cells (CAR-C1) bound to autologous TRBC1, masking TRBC1
Externí odkaz:
https://doaj.org/article/24f590f3613c4ae0a76c5fee0d280096
Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades
Autor:
Weiping Liu, Xinqiang Ji, Yuqin Song, Xiaopei Wang, Wen Zheng, Ningjing Lin, Meifeng Tu, Yan Xie, Lingyan Ping, Zhitao Ying, Chen Zhang, Lijuan Deng, Meng Wu, Feier Feng, Xin Leng, Yingli Sun, Tingting Du, Jun Zhu
Publikováno v:
Cancer Medicine, Vol 9, Iss 11, Pp 3765-3774 (2020)
Abstract Background The treatment outcomes and prognosis of lymphoma are affected by various factors such as hospital types. This study was to describe the temporal trend in the survival of lymphoma in an academic center in China. Methods A total of
Externí odkaz:
https://doaj.org/article/0df58d9410af481ea37a5eb1f5839b97
Autor:
Shaoxuan Hu, Ningjing Lin, Jiaxin Liu, Yan Sun, Weiping Liu, Xiaopei Wang, Yan Xie, Yuqin Song, Yi Wen, Jun Zhu
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundThe optimal first-line treatment for extra-nodal NK/T-cell lymphoma (ENKTL) has not been well-defined. This study aimed to evaluate the efficacy and safety of pegaspargase, cyclophosphamide, vincristine, etoposide and prednisone (COEPL) reg
Externí odkaz:
https://doaj.org/article/c056149ec7044e93826f8e0555650564